Catalog No. |
TD-VK565296 |
Species reactivity |
SARS-CoV-2 (2019-nCoV) |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
IgG1, kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P0DTC2-2 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
BMS986414,BMS-986414,BMS986414,C-135-LS,CAS:2599039-60-6 |
Background |
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |